Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
TOKYO and CAMBRIDGE, Mass., Jan. 31, 2025 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and […]
LyondellBasell reports 2024 earnings
LYB remained sharply focused on executing its three-pillar strategy Generated $3.8 billion of cash from operating activities with 90% cash […]
Signing Day Sports Retains Rights as “National Recruiting Partner” to U.S. Army Bowl Through 2026 in New Deal
SCOTTSDALE, Ariz., Jan. 31, 2025 (GLOBE NEWSWIRE) — Signing Day Sports, Inc. (“Signing Day Sports” or the “Company”) (NYSE American: […]
Zapp EV Reports Fiscal Year 2024 Financial Results
LONDON, Jan. 31, 2025 (GLOBE NEWSWIRE) — Zapp Electric Vehicles Group Limited (Nasdaq: ZAPP) (“Zapp EV” or the “Company”), owner […]
Banco Santander-Chile Announces Fourth Quarter 2024 Earnings
SANTIAGO, Chile, Jan. 31, 2025 (GLOBE NEWSWIRE) — Banco Santander Chile (NYSE: BSAC; SSE: Bsantander) announced today its results1 for […]
NIO Inc. Announces Completion of the Repurchase Right Offer for Its 0.50% Convertible Senior Notes due 2027
SHANGHAI, Jan. 31, 2025 (GLOBE NEWSWIRE) — NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a […]
Aduro Clean Technologies dépose une nouvelle demande de brevet pour la conception d’un procédé innovant
LONDON, Province de l’Ontario, 31 janv. 2025 (GLOBE NEWSWIRE) — Aduro Clean Technologies Inc, ci-après « Aduro » ou la « Société », (NASDAQ : […]
Aduro Clean Technologies meldet neues Patent für neuartiges Verfahrensdesign an
LONDON, Ontario, Jan. 31, 2025 (GLOBE NEWSWIRE) — Aduro Clean Technologies Inc. („Aduro“ oder das „Unternehmen“) (Nasdaq: ADUR) (CSE: ACT) (FSE: 9D5), ein […]
Viper Energy Announces Pricing of Upsized Class A Common Stock Offering
MIDLAND, Texas, Jan. 30, 2025 (GLOBE NEWSWIRE) — Viper Energy, Inc. (NASDAQ: VNOM) (“Viper”) announced today the pricing of an […]
Maze Therapeutics Announces Pricing of Upsized Initial Public Offering
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) — Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing […]
